Koo et al. [9] found that GDF-15 levels were considerably greater in NASH patients than in control participants and NAFLD patients in a biopsy-confirmed NAFLD cohort. This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatohepatitis.